Genentech

#Breaking: @US_FDA approved our immunotherapy as an adjuvant treatment option for adults with muscle-invasive bladder cancer (#MIBC) after surgery (cystectomy) who have circulating tumor DNA (ctDNA) molecular residual disease. Learn more: gene.com/media/press-re…

At the Association for Research in Vision and Ophthalmology Annual Meeting, we’re sharing key real-world, product and pipeline data from our ophthalmology portfolio. Learn more: gene.com/media/press-re… #ARVO2026

Launching today, All Eyes on DME is our new campaign highlighting diabetic macular edema (DME), an often overlooked eye condition linked to diabetes. Learn more: gene.com/media/press-re…

#Breaking: At the 2026 AAN Annual Meeting (#AANAM), we unveiled positive comprehensive results from our Phase III trials evaluating our investigational BTK inhibitor (BTKi) in people living with relapsing multiple sclerosis (RMS). Learn more: gene.com/media/press-re…

#Breaking: At #AANAM, we announced positive results from our Phase III study in myelin oligodendrocyte glycoprotein antibody disease (MOGAD). Learn more: gene.com/media/press-re…

#Breaking: The @US_FDA accepted our supplemental Biologics License Application for our medicine to treat systemic lupus erythematosus (SLE), the most common form of #lupus, based on positive Phase III data. If approved, it would be the first therapy to directly target B cells in SLE. Learn more: [gene.com/media/press-re…]

#Breaking: Today meaningful data from our Phase III study in systemic lupus erythematosus was published in @NEJM. Learn more: gene.com/media/press-re…

#Breaking: Positive Phase II results for our investigational long‑acting amylin analog with Zealand Pharma mark an important step forward as we move from a one‑size‑fits‑all approach to more tailored options for people living with #obesity. gene.com/media/press-re…

#Breaking: Today we announced positive additional Phase III clinical results of our investigational BTK inhibitor in people living with relapsing multiple sclerosis (RMS). Learn more: gene.com/media/press-re…

#Breaking: @US_FDA approved our new combination regimen as the first and only all-oral, fixed-duration treatment for previously untreated adults with chronic lymphocytic leukemia (CLL). Learn more: gene.com/media/press-re…

#Breaking: @US_FDA accepts New Drug Application for our investigational oral therapy in ER+ advanced #BreastCancer. Learn more: gene.com/media/press-re…

#Breaking: Today we announced positive Phase III data in primary membranous nephropathy. Learn more: gene.com/media/press-re…

#Breaking: At the #ACTRIMSForum, we revealed the full results from our Phase III clinical study of our investigational BTK inhibitor (BTKi) in primary progressive multiple sclerosis (PPMS). Read more: gene.com/media/press-re…

#Breaking: Today we announced positive Phase II results for our dual GLP-1/GIP receptor agonist for people living with #obesity. Learn more: gene.com/media/press-re…

#Breaking: Today, we announced an expansion of our investment in Holly Springs, NC, to approximately $2B. This investment supports the production of next-generation medicines for metabolic disorders, including obesity. We’re proud to be part of North Carolina’s growing biotech ecosystem. gene.com/media/press-re…

#Breaking: The @US_FDA approved our new subcutaneous formulation for the treatment of third-line or later relapsed or refractory follicular lymphoma (FL). Learn more about how we’re developing patient-centered solutions: gene.com/media/press-re…

#Breaking: At #SABCS25, we’re presenting transformational data from our positive Phase III study for people with ER+, HER2-, early-stage breast cancer. Learn more: gene.com/media/press-re…

#Breaking: Data at #ASH25 highlights the potential of our combination therapy in earlier lines for hard-to-treat blood cancers. Learn more: gene.com/media/press-re…

#Breaking: New Phase III trial data show significant improvement in invasive disease-free survival for ER+, HER2- early-stage #BreastCancer. Learn more: gene.com/media/press-re…

#Breaking: Today we announced positive Phase III clinical results of our investigational BTK inhibitor in primary progressive multiple sclerosis (PPMS) and relapsing multiple sclerosis (RMS). Learn more: gene.com/media/press-re…